^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MYB-NFIB fusion

i
Other names: MYB, MYB Proto-Oncogene, Transcription Factor, V-Myb Avian Myeloblastosis Viral Oncogene Homolog, Transcriptional Activator Myb, Proto-Oncogene C-Myb, Oncogene AMV, C-Myb_CDS, C-Myb, Cmyb, NFIB, Nuclear Factor I B, CCAAT-Box-Binding Transcription Factor, Nuclear Factor 1 B-Type, TGGCA-Binding Protein, Nuclear Factor I/B, Nuclear Factor 1/B, NFI-RED, NF-I/B, NF1-B, NFI-B, NFIB2, NFIB3, CTF, HMGIC/NFIB, MACID
Entrez ID:
Related biomarkers:
1year
Targeted RNA Sequencing of Head and Neck Adenoid Cystic Carcinoma Reveals SEC16A::NOTCH1 Fusion and MET Exon 14 Skipping as Potentially Actionable Alterations. (PubMed, Head Neck Pathol)
The study improved the understanding of AdCC providing the first documentation of tumor clinical behavior associated with MYB::MPDZ and FUS::MYB fusions and reporting potentially actionable SEC16A::NOTCH1 fusion and MET exon 14 skipping mutation. Further research is needed to explore the therapeutic utility of MET inhibition and the efficacy of γ-secretase inhibitors against rare NOTCH1 fusions in AdCC.
Retrospective data • Journal • IO biomarker
|
MET (MET proto-oncogene, receptor tyrosine kinase) • NOTCH1 (Notch 1) • MYB (MYB Proto-Oncogene, Transcription Factor) • FUS (FUS RNA Binding Protein) • NFIB (Nuclear Factor I B) • MYBL1 (MYB Proto-Oncogene Like 1)
|
MET exon 14 mutation • MET mutation • MET D1010N • MYB-NFIB fusion
1year
Adenoid Cystic Carcinoma with Sebaceous Differentiation and MYB::NFIB Fusion Arising in the External Auditory Canal. (PubMed, Head Neck Pathol)
Adenoid cystic carcinoma arising in the external auditory canal is rare, and even rarer are cases with sebaceous differentiation mimicking sebaceous carcinoma. This case with clinical, radiologic, gross, and histologic images exemplifies an unusual occurrence of adenoid cystic carcinoma in the external auditory canal with sebaceous differentiation, confirmed by MYB::NFIB fusion.
Journal
|
NFIB (Nuclear Factor I B)
|
MYB-NFIB fusion
over1year
Impact of NOTCH1 expression in primary breast adenoid cystic carcinoma. (PubMed, J Clin Pathol)
Our study demonstrates that in patients with breast AdCC, overexpression of NOTCH1 ≥20% is associated with larger tumour size and aggressive clinical outcomes. Importantly, NOTCH1 inhibitors may have potential therapeutic effect in patients with breast AdCC.
Journal
|
NOTCH1 (Notch 1) • NFIB (Nuclear Factor I B)
|
NOTCH1 expression • MYB-NFIB fusion • NOTCH1 overexpression
almost2years
Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements. (PubMed, Gynecol Oncol)
AdCC-BGs constitute a convergent phenotype, whereby activation of MYB or MYBL1 can be driven by the MYB::NFIB fusion gene or MYBL1 rearrangements. Our observations further support the notion that AdCCs, irrespective of organ site, constitute a genotypic-phenotypic correlation. Assessment of MYB or MYBL1 rearrangements may be used as an ancillary marker for the diagnosis of AdCC-BGs.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • GNAQ (G Protein Subunit Alpha Q) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • EWSR1 (EWS RNA Binding Protein 1) • RAD51B (RAD51 Paralog B) • KDM6A (Lysine Demethylase 6A) • GNAS (GNAS Complex Locus) • NFIB (Nuclear Factor I B) • MYBL1 (MYB Proto-Oncogene Like 1)
|
MYB-NFIB fusion
almost2years
Adenoid Cystic Carcinoma of the Vulva and Vagina: A Clinicopathologic, Immunohistochemical, and Molecular Characterization of Five Cases. (PubMed, Int J Gynecol Pathol)
There were no MYBL1 or NFIB rearrangements and no MYB::NFIB fusions. Our findings corroborate that the histologic, immunohistochemical, and oncogenic background is similar between ACCs of the lower female genital tract and ACCs elsewhere, although the canonical MYB::NFIB fusion seems to be a less common finding in this location.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • NFIB (Nuclear Factor I B) • ANO1 (Anoctamin 1) • MYBL1 (MYB Proto-Oncogene Like 1)
|
MYB-NFIB fusion
2years
Molecular characterisation of tumours of the lacrimal apparatus. (PubMed, Histopathology)
Our study highlights the variety of molecular alterations associated with lacrimal system tumours and emphasises the importance of molecular testing in these tumours, which can reveal potentially targetable mutations. Our results also reinforce the hypothesis of a common physiopathology of all ACCs, regardless of their primary location.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • FGFR2 (Fibroblast growth factor receptor 2) • ATM (ATM serine/threonine kinase) • NOTCH1 (Notch 1) • NFIB (Nuclear Factor I B) • MYBL1 (MYB Proto-Oncogene Like 1)
|
TP53 mutation • HER-2 amplification • HER-2 mutation • ATM mutation • FGFR2 mutation • FGFR2 fusion • CIC mutation • MYB-NFIB fusion
2years
The Role of Novel Immunohistochemical Markers for Special Types of Breast Carcinoma. (PubMed, Adv Anat Pathol)
Immunohistochemical antibodies have emerged that identify the underlying genetic alterations in these tumors and serve as useful diagnostic tools. This review will provide an update on the molecular features and diagnostic immunohistochemical markers that have become increasingly popular to aid in diagnosing these uncommon triple-negative breast tumors.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • MYB (MYB Proto-Oncogene, Transcription Factor) • NFIB (Nuclear Factor I B)
|
NTRK3 fusion • HER-2 expression • ETV6-NTRK3 fusion • MYB-NFIB fusion
over2years
Solid-basaloid adenoid cystic carcinoma of the breast: an aggressive subtype enriched for Notch pathway and chromatin-modifier mutations with MYB overexpression. (PubMed, Mod Pathol)
The data highlight the histopathologic spectrum of basaloid carcinomas including SB-AdCC and reveal shared genetics and MYB activation, which can be diagnostically useful. Aggressive behavior and poor treatment responses emphasize a need for additional treatment approaches.
Journal
|
TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NOTCH1 (Notch 1) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • SOX10 (SRY-Box 10) • NFIB (Nuclear Factor I B) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
|
TP53 mutation • MYB-NFIB fusion
over2years
A RARE CASE OF ADENOID CYSTIC CARCINOMA OF THE LUNG (CHEST 2023)
This case highlights a rare presentation of primary adenoid cystic carcinoma of the lung treated with curative robot assisted surgical resection.
Clinical
|
NFIB (Nuclear Factor I B) • MYBL1 (MYB Proto-Oncogene Like 1)
|
MYB-NFIB fusion
over2years
Increased retinoic acid signaling decreases lung metastasis in salivary adenoid cystic carcinoma by inhibiting the noncanonical Notch1 pathway. (PubMed, Exp Mol Med)
Bioinformatic, RNA-seq, and immunohistochemical (IHC) analyses of primary tissues and metastatic lung tissues from patients with SACC suggested that RA system insufficiency partially promotes lung metastasis. These findings imply the value of the RA system in diagnosis and treatment.
Journal
|
NOTCH1 (Notch 1) • MYB (MYB Proto-Oncogene, Transcription Factor) • NFIB (Nuclear Factor I B)
|
NOTCH1 mutation • NOTCH1 expression • MYB-NFIB fusion